-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanjing Leads Biolabs says LBL-047 Phase I trial starts in China for lupus

PUBT·05/06/2026 00:30:21
Listen to the news
Nanjing Leads Biolabs says LBL-047 Phase I trial starts in China for lupus
  • Nanjing Leads Biolabs partner Dianthus Therapeutics prioritized LBL-047 for clinical development in Sjögren’s disease, systemic lupus erythematosus, and dermatomyositis, positioning the asset as a core program for multiple autoimmune indications.
  • Phase I study started in China in December 2025, enrolling healthy volunteers and systemic lupus erythematosus patients, with results not yet presented.
  • Top-line readout from healthy-volunteer cohort expected in 2H 2026, setting up decisions on next clinical steps across prioritized indications.
  • Dianthus completed an upsized underwritten public offering in March 2026 that raised about USD 719 million, strengthening funding for global development.
  • LBL-047 combines two mechanisms intended to reduce autoimmune activity, supporting a potential subcutaneous self-administration regimen with dosing every four weeks or less.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260506-12147223), on May 06, 2026, and is solely responsible for the information contained therein.